Ipsen’s Palovarotene Hit By FDA Clinical Hold
Analysts Cut Their Palovarotene Sales Projections
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
